Federal Register / Vol. 56, No. 213 / Monday, November 4, 1991 / Notices 
56415 
discuss whether continued availability of the 
device(s) is necessary for the public health. 
Dated: October 28. 1991. 
Michael R. Taylor, 
Deputy Commissioner for Policy. 
|FR Doc. 91-26462 Filed 11-1-91: 8:45 am] 
BILLING CODE 4160-01-M 
Health Resources and Services 
Administration 
Advisory Council; Meeting 
In accordance with section 10(a)(2) of 
the Federal Advisory Committee Act 
(Pub. L. 92-463), announcement is made 
of the following National Advisory body 
scheduled to meet during the month of 
November 1991: 
Name: Advisory Council on Nurses 
Education. 
Date and Time: November 21-22, 1991. 
9 a.m.-5 p.m. 
Place : Conference Room K, Parklawn 
Building: 5600 Fishers Lane, Rockville, 
Maryland 20857. 
Closed on November 21, 9 a.m.-3 p.m. 
Open for remainder of meeting. 
Purpose: The Council advises the 
Secretary and Administrator, Health 
Resources and Services Administration, 
concerning general regulations and 
policy matters arising in the 
administration of the Nursing Shortage 
Reduction and Education Extension Act 
of 1988 (Pub. L. 100-607). The Council 
also performs final review of grant 
applications for Federal Assistance, and 
makes recommendations to the 
Administrator, HRSA. 
Agenda: The open portion of the 
meeting will cover announcements: 
considerations of minutes of previous 
meeting: the reports of the 
Administrator, Health Resources and 
Services Administration, the Director, 
Division of Nursing and staff reports. 
The meeting will be closed to the public 
on November 21, from 9 a.m. to 3 p.m. 
for the review of grant applications for 
Special Project Grants; Nursing 
Education Opportunities for Individuals 
from Disadvantaged Backgrounds, 
Advance Nurse Education and Nurse 
Practitioner Grants. The closing is in 
accordance with the provisions set forth 
in section 552b(c)(6), title 5 U.S.C. Code, 
and the Determination by the 
Administrator, Health Resources and 
Services Administration, pursuant to 
Public Law 92—463. Anyone requiring 
information regarding the subject 
Council should contact Dr. Mary S. Hill, 
Executive Secretary. Advisory Council 
on Nurses Education, room 5C-14, 
Parklawn Building, 5600 Fishers Lane, 
Rockville, Maryland 20857, Telephone 
(301 ) 443-6193. 
Agenda Items are subject to change as 
priorities dictate. 
Dated: October 29, 1991. 
Jackie E. Baum, 
Advisory Committee Management Officer. 
HRSA. 
(FR Doc. 91-26463 Filed 11-1-91; 8:45 am] 
BILLING CODE 4160-1S-M 
National Institutes of Health 
National Institute on Deafness and 
Other Communication Disorders; 
Meeting of the National Deafness and 
Other Communication Disorders 
Advisory Board 
Pursuant to Public Law 92-463, notice 
is hereby given of the meeting of the 
National Deafness and Other 
Communication Disorders Advisory 
Board on November 18, 1991. The 
meeting will take place from 8:30 a.m. to 
4:30 p.m. in Conference Room 6, Building 
31C, National Institutes of Health, 9000 
Rockville Pike, Bethesda, Maryland 
20892. 
The meeting will be open to the public 
to discuss the Board’s activities and to 
present special reports. Attendance by 
the public will be limited to the space 
available. 
Summaries of the Board’s meeting and 
a roster of members may be obtained 
from Mrs. Monica Davies, National 
Institute on Deafness and Other 
Communication Disorders, Building 31, 
room 3C08, National Institutes of Health, 
Bethesda, Maryland 20892, 301-402- 
1129, upon request. 
(Catalog of Federal Domestic Assistance 
Program No. 13.173 Biological Research 
Related to Deafness and Other 
Communication Disorders.) 
Dated: October 24, 1991. 
Raymond Bahor, 
Acting Committee Management Officer, NIH. 
(FR Doc. 91-26482 Filed 11-1-91; 8:45 am] 
BILLING CODE 414Q-01-M 
Human Gene Therapy Subcommittee; 
Meeting 
Pursuant to Public Law 92-463, notice 
is hereby given of a meeting of the 
Human Gene Therapy Subcommittee (a 
subcommittee of the Recombinant DNA 
Advisory Committee) on November 21- 
22, 1991. The meeting will be held at the 
National Institutes of Health (NIH), 
Building 31, Conference Room 6, 9000 
Rockville Pike. Bethesda, Maryland 
20892, starting on November 21 at 
approximately 9 a.m. to adjournment on 
November 22 at approximately 5 p.m. 
The meeting will be open to the public 
to discuss the following proposed 
actions under the NIH Guidelines for 
Research Involving Recombinant DNA 
Molecules (51 FR 16958): 
I. Addition to Appendix D of the “NIH 
Guidelines" Regarding a Human Gene 
Therapy Protocol/Dr. Nabel 
In a letter dated October 18, 1991, Dr. 
Gary J. Nabel of the University of 
Michigan Medical School indicated his 
intention to submit a human gen? 
therapy protocol to the Human Gene 
Therapy Subcommittee and the 
Recombinant DNA Advisory Committee 
for formal review and approval. The title 
of this protocol is: “Immunotherapy of 
Malignancy by In Vivo Gene Transfer 
Into Tumors." 
II. Addition to Appendix D of the “NIH 
Guidelines" Regarding a Human Gene 
Transfer Protocol/Dr. Cometta 
In a letter dated October 10, 1991, Dr. 
Kenneth Cometta of Indiana University 
indicated his intention to submit a 
human gene transfer protocol to the 
Human Gene Therapy Subcommittee 
and the Recombinant DNA Advisory 
Committee for formal review and 
approval. The title of this protocol is: 
“Retroviral-Mediated Gene Transfer of 
Bone Marrow Cells During Autologous 
Bone Marrow Transplantation for Acute 
Leukemia." 
III. Addition to Appendix D of the “NIH 
Guidelines” Regarding a Human Gene 
Transfer Protocol/Dr. Economou 
In a letter dated October 15, 1991, Dr. 
James S. Economou of the University of 
California, Los Angeles, indicated his 
intention to submit a human gene 
transfer protocol to the Human Gene 
Therapy Subcommittee and the 
Recombinant DNA Advisory Committee 
for formal review and approval. The title 
of this protocol is: “The Treatment of 
Patients with Metastatic Melanoma and 
Renal Cell Cancer Using In Vitro 
Expanded and Genetically-Engineered 
(Neomycin Phosphotransferase) Bulk, 
CD8( + ) and/or CD4( + ) Tumor 
Infiltrating Lymphocytes and Bulk, 
CD8(-|-) and/or CD4( + ) Peripheral 
Blood Leukocytes in Combination with 
Recombinant Interleukin-2 Alone, or 
with Recombinant Interleukin-2 and 
Recombinant Alpha Interferon." 
IV. Addition to Appendix D of the “NIH 
Guidelines” Regarding a Human Gene 
Therapy Protocol/Dr. Sobol 
In a letter dated October 18, 1991, Dr. 
Robert E. Sobol of the University of 
California, San Diego, indicated his 
intention to submit a human gene 
therapy protocol to the Human Gene 
Therapy Subcommittee and the 
Recombinant DNA Research, Volume 15 
[219] 
